Jon Congleton - Jun 12, 2024 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Chief Executive Officer, Director
Signature
/s/ Adam Levy, Attorney-in-fact
Stock symbol
MLYS
Transactions as of
Jun 12, 2024
Transactions value $
-$924,203
Form type
4
Date filed
6/14/2024, 06:15 PM
Previous filing
Feb 15, 2024
Next filing
Jun 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MLYS Common Stock Sale -$212K -16.6K -1.58% $12.77 1.03M Jun 12, 2024 Direct F1, F2
transaction MLYS Common Stock Sale -$509K -40K -3.87% $12.74 993K Jun 13, 2024 Direct F1, F3
transaction MLYS Common Stock Sale -$203K -16.2K -1.64% $12.52 976K Jun 14, 2024 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2024.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.4587 to $13.35. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.49 to $13.04.
F4 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.39 to $12.635.